

## Clinical Impact of Asymptomatic Presentation Status in Patients With Paroxysmal and Sustained Atrial Fibrillation:

Esato, Masahiro; Chun, Yeong-hwa; An, Yoshimori; Ogawa, Hisashi; Wada, Hiromichi; Hasegawa, Koji; Tsuji, Hikari; Abe, Mitsuru; Lip, Gregory Y.h.; Akao, Masaharu

DOI:

[10.1016/j.chest.2017.08.004](https://doi.org/10.1016/j.chest.2017.08.004)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Esato, M, Chun, Y, An, Y, Ogawa, H, Wada, H, Hasegawa, K, Tsuji, H, Abe, M, Lip, GYH & Akao, M 2017, 'Clinical Impact of Asymptomatic Presentation Status in Patients With Paroxysmal and Sustained Atrial Fibrillation: The Fushimi AF Registry', *Chest*. <https://doi.org/10.1016/j.chest.2017.08.004>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.


When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# Accepted Manuscript



Clinical Impact of Asymptomatic Presentation Status in Patients with Paroxysmal and Sustained Atrial Fibrillation: The Fushimi AF Registry

Masahiro Esato, MD, PhD, Yeung-Hwa Chun, MD, PhD, Yoshimori An, MD, Hisashi Ogawa, MD, Hiromichi Wada, MD, PhD, Koji Hasegawa, MD, PhD, Hikari Tsuji, MD, PhD, Mitsuru Abe, MD, PhD, Gregory Y.H. Lip, MD, Masaharu Akao, MD, PhD

PII: S0012-3692(17)31397-1

DOI: [10.1016/j.chest.2017.08.004](https://doi.org/10.1016/j.chest.2017.08.004)

Reference: CHEST 1247

To appear in: *CHEST*

Received Date: 12 April 2017

Revised Date: 17 July 2017

Accepted Date: 1 August 2017

Please cite this article as: Esato M, Chun YH, An Y, Ogawa H, Wada H, Hasegawa K, Tsuji H, Abe M, Lip GYH, Akao M, Clinical Impact of Asymptomatic Presentation Status in Patients with Paroxysmal and Sustained Atrial Fibrillation: The Fushimi AF Registry, *CHEST* (2017), doi: 10.1016/j.chest.2017.08.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Title:**

ACCEPTED MANUSCRIPT

Clinical Impact of Asymptomatic Presentation Status in Patients with Paroxysmal and Sustained Atrial Fibrillation: The Fushimi AF Registry.

**Authors:**

Masahiro Esato, MD, PhD<sup>1</sup>; Yeung-Hwa Chun, MD, PhD<sup>1</sup>; Yoshimori An, MD<sup>2</sup>; Hisashi Ogawa, MD<sup>2</sup>; Hiromichi Wada, MD, PhD<sup>3</sup>; Koji Hasegawa, MD, PhD<sup>3</sup>; Hikari Tsuji, MD, PhD<sup>4</sup>; Mitsuru Abe, MD, PhD<sup>2</sup>; Gregory Y.H. Lip, MD<sup>5\*</sup>; Masaharu Akao, MD, PhD<sup>2\*</sup> [\*joint senior authors]

**Institutions:**

<sup>1</sup>Department of Arrhythmia, Ijinkai Takeda General Hospital, Japan

<sup>2</sup>Department of Cardiology, National Hospital Organization Kyoto Medical Center, Japan

<sup>3</sup>Division of Translational Research, National Hospital Organization Kyoto Medical Center, Japan

<sup>4</sup>Tsuji Clinic, Japan

<sup>5</sup>Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

**Corresponding author:**

Masaharu Akao, MD, PhD

Department of Cardiology, National Hospital Organization Kyoto Medical Center,

1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan.

E-mail: akao@kuhp.kyoto-u.ac.jp

**Short Title:**

Asymptomatic Patients with Paroxysmal and Sustained AF

No. of Manuscript pages: 25

No. of Figures: 2

No. of Tables: 5

ACCEPTED MANUSCRIPT

**Abstract**

*Background:* The clinical characteristics and outcomes of asymptomatic patients with paroxysmal or

persistent/permanent atrial fibrillation (AF) are largely unknown.

*Methods:* The Fushimi AF Registry is a community-based prospective survey of AF patients who visited the participating medical institutions in Fushimi-ku, Japan. We investigated the clinical characteristics and outcomes of asymptomatic versus symptomatic patients in the paroxysmal (n=1,837) and persistent/permanent (as sustained: n=1,912) AF subgroups.

*Results:* In the paroxysmal AF (PAF) group, asymptomatic patients were older (*asymptomatic vs. symptomatic*: 74.1 vs. 71.1 years of age;  $p < 0.01$ ), more often male (62.1% vs. 55.6%;  $p < 0.01$ ), and had a higher CHA<sub>2</sub>DS<sub>2</sub>-VASc score (mean  $3.37 \pm 1.73$  vs.  $2.99 \pm 1.63$ ;  $p < 0.01$ ), while the prevalence of major comorbidities and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were comparable in the sustained AF (SAF) group. Multivariable analysis indicated that age ( $\geq 75$  years), history of stroke/SE, male sex, and chronic kidney disease were independent determinants of asymptomatic status in the PAF group, while age was non-significant in the SAF group. During the follow-up period, all-cause mortality was significantly higher (hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.31-2.29;  $p < 0.01$ ) in asymptomatic patients compared with symptomatic patients in the PAF group, while it was comparable in the SAF group.

*Conclusions:* Asymptomatic clinical status is associated with older age, males, more co-morbidities with higher stroke risk profile, and a higher incidence of all-cause death in patients with PAF, whereas these characteristics and outcomes were not seen in the SAF group.

Clinical Trial Registration: URL: <http://www.umin.ac.jp/ctr/index.htm>

Unique identifier: UMIN000005834.

Detection and diagnosis of atrial fibrillation (AF) can be challenging in patients who are asymptomatic or minimally symptomatic, regardless of whether it is paroxysmal or persistent/permanent.<sup>1</sup> Undiagnosed asymptomatic AF is important and may lead to a first presentation with acute ischaemic stroke or decompensated heart failure.<sup>2</sup>

Several studies have compared the clinical characteristics and outcomes in asymptomatic and symptomatic AF patients; however, the majority of patients in these studies had persistent or permanent AF, and were reported from Western population cohorts.<sup>3-5</sup> There are limited data on differences in the clinical characteristics and outcomes of community-based asymptomatic AF patients with paroxysmal and persistent/permanent AF, particularly from Asian cohorts.

The aim of this study was to investigate the clinical profile and outcomes of asymptomatic AF patients, when compared with symptomatic patients, with paroxysmal and sustained (i.e. persistent/permanent) AF from the Fushimi AF registry, a community-based prospective survey of Japanese patients with AF.<sup>6-8</sup>

## **Methods**

### ***Study Cohort***

The detailed study design, patient enrollment, the definition of measurements, and subjects' baseline clinical characteristics in the Fushimi AF Registry were previously described (UMIN Clinical Trials Registry: UMIN000005834).<sup>6</sup> The inclusion criterion for the registry is the documentation of AF on a 12-lead ECG or Holter monitoring at any time. There are no exclusion criteria. Patient enrollment was started in March 2011. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and was

approved by the ethics committees of the National Hospital Organization Kyoto Medical Center and Ijinkai

Takeda General Hospital.

### ***Cohort Classification***

The entire cohort was divided into two subgroups of AF defined as follows: (i) Paroxysmal AF (PAF), defined as self-terminating episodes lasting less than 7 days; and (ii) Sustained AF (SAF), defined as either persistent (episodes lasting longer than 7 days which can be terminated either by pharmacological therapy or electric cardioversion) or permanent (AF that is accepted by the patient (and physician), for which rhythm control interventions are not pursued) AF.<sup>9,10</sup> The patients were subsequently differentiated as being either asymptomatic or symptomatic at the time of enrollment based on their physicians' diagnosis and/or discretion. The symptoms of each patient were broadly described as one of the following: palpitations, orthopnea, fatigue, chest pain, and faintness; and patients were categorized into asymptomatic when the patient did not have any symptoms. The baseline characteristics and clinical outcomes of asymptomatic and symptomatic AF patients were compared in the PAF and SAF groups.

### ***Study Endpoints***

The clinical endpoints in this analysis were the incidence of stroke/SE, all-cause mortality, heart failure (HF) admission, and major bleeding during the follow-up period. These endpoints were also analyzed in the subgroups stratified by OAC use at baseline. OACs included warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban. Stroke was defined as the sudden onset of a focal neurologic deficit in a location consistent with the territory of a major cerebral artery, and the diagnosis of ischemic or hemorrhagic stroke was

confirmed by computed tomography or magnetic resonance imaging. SE was defined as an acute vascular occlusion of an extremity or organ. Major bleeding was defined as a reduction in the hemoglobin level of  $\geq 2$  g/dl, transfusion of  $\geq 2$  units of blood, or symptomatic bleeding in a critical area or organ. HF was defined by clinical symptoms and signs, with a comprehensive examination to confirm the underlying cardiac disorder.

### **Statistical Analyses**

Continuous variables are expressed as mean  $\pm$  standard deviation (SD) or median and interquartile range (IQR). Categorical variables are presented as numbers and percentages. We compared categorical variables using the chi-square test when appropriate; otherwise, we used the Fisher's exact test. The Kaplan-Meier method was used to estimate the cumulative incidence of each clinical event. We conducted a multivariable analysis using a logistic regression method to investigate the independent determinants of asymptomatic clinical status. The covariates chosen to be included in model were male sex, coronary artery disease, chronic kidney disease (CKD; persistent proteinuria or estimated glomerular filtration rate  $< 60 \text{ ml/min/1.73m}^2$ ),<sup>11</sup> and components of the CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score (congestive heart failure, hypertension, age  $\geq 75$  years, diabetes mellitus, history of stroke, vascular disease, age 65-74 years and female sex).<sup>12</sup> A multivariable Cox proportional hazard model was used to calculate the hazard ratios (HRs) of asymptomatic status for major clinical events in the PAF patients. Covariates chosen to be included in the model were age, body weight, history of stroke/SE, history of heart failure, hypertension, diabetes mellitus, coronary artery disease, peripheral artery disease, CKD, and history of major bleeding.

Data were analyzed with the use of the online software, 'EZR' (Easy R 32-bit version; <http://www.jjichi.ac.jp/saitama-sct/SaitamaHP.files/statmed.html>), for Windows.<sup>13</sup> A two-sided P-value  $< 0.05$



was considered statistically significant. Confidence intervals (CI) are reported as 95%.

## **Results**

A total of 4,484 patients were enrolled by the end of December 2015. Of the 4,185 patients who were enrolled 1 year prior (by the end of December 2014), follow-up data (collected every year) were available for 3,749 patients (follow-up rate: 89.6%). Of these 3,749 patients, 1,971 patients (52.6%) were asymptomatic, and the remaining 1,778 (47.4%) patients were symptomatic; 1,837 patients (49%) had PAF and 1,912 patients (51%) had SAF. Furthermore, 689 patients (37.5%) and 1,282 patients (67.1%) were asymptomatic in the PAF and SAF group, respectively. Median follow-up was 1,099 days (IQR 479–1719 days).

### ***Baseline Clinical Characteristics***

Mean ( $\pm$ SD) age and CHA<sub>2</sub>DS<sub>2</sub>-VASc score in the entire cohort were 73.6 ( $\pm$ 11) years, and 3.37 ( $\pm$ 1.7), respectively. Asymptomatic patients were older, and had a higher mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score than symptomatic patients in the entire cohort (asymptomatic vs. symptomatic: 74.7 ( $\pm$ 10.6) vs. 72.4 ( $\pm$ 11.3);  $P < 0.01$ , and 3.49 ( $\pm$ 1.72) vs. 3.23 ( $\pm$ 1.68);  $P < 0.01$ , respectively).

Baseline clinical characteristics of asymptomatic and symptomatic patients in both the PAF and SAF groups are summarized in Table 1. In the PAF group, asymptomatic patients were more often male, older, and were more likely to have a history of stroke/SE, CKD, and major bleeding. Both the mean CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were higher in asymptomatic patients. There was less use of class I antiarrhythmic drugs (AAD), and  $\beta$ -blockers in the asymptomatic patients compared with symptomatic ones, whereas the OAC use was similar. In the SAF group, asymptomatic patients were often male and were more likely to

have a history of stroke/SE, but the mean CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were similar. There was a lower rate of class I antiarrhythmic drug (AAD),  $\beta$ -blocker, and diuretics use in asymptomatic patients. The use of OACs was also lower in asymptomatic patients than in symptomatic patients. A lower proportion of asymptomatic patients underwent invasive catheter ablation compared with symptomatic patients in both PAF and SAF groups.

On multivariable logistic regression analysis, male sex, age ( $\geq 75$  years), CKD, history of stroke/SE, and major bleeding were significantly associated with asymptomatic status in the PAF group, after adjusting for several covariates including the components of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score (Table 2). In the SAF group, the same covariates as in the PAF group, with the exception of age, were also significantly associated with asymptomatic status.

### ***Clinical Outcomes***

Major clinical events in the PAF or SAF group and in the entire cohort during the follow-up period are shown in Table 3. Kaplan-Meier curves for the incidences of stroke/SE, all-cause mortality, HF admission, and major bleeding are shown in Figure 1 (PAF group) and Figure 2 (SAF group).

In the PAF group, all-cause mortality was significantly higher in asymptomatic patients compared with symptomatic patients (asymptomatic versus symptomatic: 7.25 versus 3.70 per 100 person-years;  $P < 0.01$ , Table 3). The mortality between asymptomatic PAF group and the entire SAF group was non-significantly different (7.25 versus 6.67 per 100 person-years;  $P = 0.11$ ). All the other outcomes (stroke/SE, HF admission, and major bleeding) were non-significantly different between asymptomatic and symptomatic patients in PAF.

On multivariable analysis, asymptomatic status was significantly associated with the higher mortality in PAF patients after adjusting for potential confounders (HR, 1.71; 95% CI, 1.31-2.29;  $P < 0.01$ ) (Table 4). The higher risk of mortality persisted even when the PAF patients were stratified by OAC status (With OAC: HR, 1.74; 95% CI, 1.12-2.71, Without OAC: HR, 1.68; 95% CI, 1.20-2.34) (Table 4). All clinical outcomes were non-significantly different between asymptomatic and symptomatic patients in the SAF group (Table 3). Finally, we explored the risk factors of all-cause death in the PAF patients, using multivariable logistic regression analysis. As shown in the Table 5, after adjusting for confounders, asymptomatic status was an independent risk factor of the incidence of all-cause death during the follow-up period in the PAF group (HR: 1.73, 95% CI: 1.29-2.33;  $P < 0.01$ ).

## **Discussion**

In this large community-based Asian cohort from Japan comparing characteristics and outcomes between paroxysmal and sustained AF patients in relation to symptomatic status, our principal findings are as follows: (i) asymptomatic patients have more comorbidities with higher CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores, a higher incidence of all-cause death compared with symptomatic patients in the PAF group, whereas these characteristics and outcomes were not seen in the SAF group; (ii) independent determinants of asymptomatic presentation were male sex, age, CKD, and prior history of stroke/SE or major bleeding in the PAF group, but not age in the SAF group; and (iii) all-cause mortality was higher in asymptomatic patients compared to symptomatic patients in the PAF group, with asymptomatic clinical status being an independent risk factor for all-cause mortality.

Asymptomatic AF is common in daily “real-world” clinical practice<sup>14-16</sup>. However, the relationship between patient characteristics and symptom presentation has not been consistent across studies and therefore remains controversial. Additionally, these relationships have not been studied in community-based PAF and SAF groups, nor in Asian AF cohorts.

In the present study, we show distinct clinical characteristics of asymptomatic and symptomatic patients in the PAF group, rather than those in the SAF group. There were more comorbidities with higher CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores in asymptomatic patients than in symptomatic in the PAF group, while these were similar in the SAF group; however, asymptomatic PAF and SAF patients have similar risks of thromboembolism. The proportions of invasive and medical treatments were similar or less frequent in asymptomatic patients compared with symptomatic patients in both the PAF and SAF groups, indicating that the symptomatic status is likely to affect the physicians' decision on treatment strategy in both PAF and SAF patients.

Male sex, CKD, and history of stroke/SE or major bleeding were significantly associated with asymptomatic status both in the PAF and SAF group. The higher prevalence of asymptomatic status in male was consistent with previous reports.<sup>17</sup> Nonetheless, we recognize that CKD and previous stroke/SE or major bleeding may be related to physical disability and/or inactivity, which could make patients asymptomatic.

### ***Clinical outcomes of asymptomatic patients in the paroxysmal and sustained AF groups***

In the present study, all-cause mortality was higher in asymptomatic than symptomatic patients, but only in the PAF group. In a study by Boriani et al.,<sup>3,15</sup> asymptomatic patients were associated with more

comorbidities, higher CHA<sub>2</sub>DS<sub>2</sub>-VASc score, and had higher mortality, compared with symptomatic patients.

They therefore concluded that asymptomatic AF is not benign but is associated with a higher mortality risk, inconsistent with prior randomized clinical trials.<sup>5,18</sup> Our present data also demonstrate worse clinical outcomes of asymptomatic patients compared with those of symptomatic patients in the PAF group, but not in the SAF group. One possible reason of these distinct outcomes between the PAF and SAF subgroups may be due to the difficulty of AF detection in patients with PAF compared with SAF. SAF can be easily detected with routine ECG even in the absence of symptoms, but PAF would be less easily detected, especially if asymptomatic. Hence, optimal AF management would be delayed or inappropriate, including OAC treatment. Indeed, asymptomatic patients were older, with more comorbidities and higher CHA<sub>2</sub>DS<sub>2</sub>-VASc score compared with symptomatic patients in the PAF group, perhaps because those patients were more likely to be undetected. In contrast, differences between asymptomatic and symptomatic patients were not observed in SAF group, which suggests similarity of AF detection irrespective of patients' symptoms.

Recent studies have reported that the patients with PAF had a lower rate of stroke/SE or mortality than those with SAF.<sup>19,20</sup> However, our present findings suggest that these outcomes were not applicable in terms of the asymptomatic clinical status. Our present study highlights the worse outcomes of asymptomatic PAF patients, that are comparable to those in patients with SAF, thus emphasizing the importance of early AF detection and holistic management in daily cardiology practice.

### **Limitations**

Several limitations should be acknowledged in interpreting the results of the present study. First, the results

are derived from an observational study, and describes associative, not causative evidence. The present data were derived from an urban district in Japan, and therefore the results cannot be easily extrapolated to other rural areas, countries, or population-based registries. Second, OAC data were collected only at the time of study entry, so we could not examine the relationship between changes in OACs and clinical events. Additionally, the type of antithrombotic drugs and doses were selected at the discretion of the attending physician. Third, we did not investigate the time in therapeutic range for patients receiving warfarin during follow-up or the adherence to OAC therapies. Therefore, it is difficult to determine the influence of the quality of warfarin control and the adherence of OAC therapies on outcomes. Fourth, we were unable to assess AF burden, which might have affected the incidence of stroke/SE in patients with PAF. Fifth, the diagnosis of the type of AF, the determination of symptomatic/asymptomatic status and the classification of symptoms were physician-dependent at the time of enrollment, which may affect the clinical profiles and outcomes. Moreover, many asymptomatic patients (at enrollment) might have been previously symptomatic, but we did not have information on prior symptom status. Indeed, Boriani et al. reported the significant difference in the patient characteristics between fully asymptomatic patients and asymptomatic patients with previous symptoms.<sup>3</sup> Sixth, there may be some selection bias for asymptomatic patients: the higher risk profiles might be more related to age rather than symptom status, as being older usually represents a longer prior AF duration which may potentially leads to an asymptomatic status. Seventh, other minor symptoms which were not categorized into any of the five pre-defined symptom types may be overlooked. We unfortunately have no data regarding the exercise capacity of asymptomatic patients, which may have a major impact on overall outcome. Finally, we cannot rule out the possibility of unmeasured or residual confounding especially with age and co-morbidities even after the multivariate analysis.

Despite these limitations, our study highlights the differences in the clinical profile and outcomes between asymptomatic and symptomatic patients in both the PAF and SAF cohorts. The present data also demonstrated that asymptomatic PAF patients may not receive adequate treatment, thus better identification and management of such patients with PAF would be needed.

### **Conclusions**

In this community-based, large prospective cohort of Japanese patients with AF, asymptomatic clinical status is associated with older age, males, more co-morbidities with higher stroke risk profile, and a higher incidence of all-cause death in patients with PAF, whereas these characteristics and outcomes were not seen in the SAF group.

M. Akao had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Author contributions:** ME analyzed the data and wrote the paper. GYHL helped data analysis and interpretation. YC, YA, HW, KH, HO, and M. Abe are executive members of the organizing committee of the Fushimi AF Registry. M. Akao is a principal investigator of the Fushimi AF Registry, and the corresponding author of this paper.

**Role of the sponsors:** The sponsors had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.

**Other contributions:** We sincerely appreciate the efforts of the clinical research coordinators (T. Shinagawa, M. Mitamura, M. Fukahori, M. Kimura, M. Fukuyama, and C. Kamata).

### **Disclosures**

Dr. Akao received lecture fees from Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Healthcare and Daiichi-Sankyo. Dr. Lip has served as a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo and has been on the speakers bureau for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

### **Sources of Funding**

The Fushimi AF Registry is supported by research funding from Boehringer Ingelheim, Bayer Healthcare,



Pfizer, Bristol-Myers Squibb, Astellas Pharma, AstraZeneca, Daiichi-Sankyo, Novartis Pharma, MSD, Sanofi-Aventis and Takeda Pharmaceutical. This research is partially supported by the Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus from Japan Agency for Medical Research and Development, AMED (15656344, 16768811).

ACCEPTED MANUSCRIPT

1. Alonso A, Bengtson LG. A rising tide: the global epidemic of atrial fibrillation. *Circulation*. 2014;129(8):829-830.
2. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med*. 2014;370(26):2478-2486.
3. Boriani G, Laroche C, Diemberger I, et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. *Am J Med*. 2015;128(5):509-518.
4. Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. *Int J Cardiol*. 2013;168(5):4744-4749.
5. Flaker GC, Belew K, Beckman K, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. *Am Heart J*. 2005;149(4):657-663.
6. Akao M, Chun YH, Wada H, et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry. *J Cardiol*. 2013;61(4):260-266.

7. Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. *Circ J.* 2014;78(9):2166-2172.
8. Yamashita Y, Hamatani Y, Esato M, et al. Clinical characteristics and outcomes in extreme elderly (Age  $\geq$  85 Years) Japanese patients with atrial fibrillation: The Fushimi AF Registry. *Chest.* 2016;149(2):401-412.
9. Takabayashi K, Hamatani Y, Yamashita Y, et al. Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation: The Fushimi Atrial Fibrillation Registry. *Stroke.* 2015;46(12):3354-3361.
10. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J.* 2016;37(38):2893-2962.
11. Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. *Clin Exp Nephrol.* 2009;13(6):537-566.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. *JAMA.* 2001;285(22):2864-2870.
13. Kanda Y. Investigation of the freely available easy-to-use software 'EZ' for medical statistics. *Bone Marrow Transplantation.* 2013;48(3):452-458.

14. Lip GY, Tse HF, Lane DA. Atrial fibrillation. *Lancet*. 2012;379(9816):648-661.
15. Boriani G, Diemberger I, Ziacchi M, et al. AF burden is important - fact or fiction? *Int J Clin Pract*. 2014;68(4):444-452.
16. Boriani G, Valzania C, Biffi M, et al. Asymptomatic lone atrial fibrillation - how can we detect the arrhythmia? *Curr Pharm Des*. 2015;21(5):659-666.
17. Schnabel RB, Pecun L, Ojeda FM, et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. *Heart*. 2017;22(0):1-7.
18. Rienstra M, Vermond RA, Crijns HJ, et al. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. *Heart Rhythm*. 2014;11(6):939-945.
19. Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. *Eur Heart J*. 2015;36(5):288-296.
20. Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. *Eur Heart J*.

## **Figure Legends**

### **Figure 1.**

Kaplan-Meier curves for the incidences of stroke/systemic embolism (SE) (**A**), All-cause death (**B**), heart failure (HF) admission (**C**), and major bleeding (D) between asymptomatic and symptomatic patients with paroxysmal atrial fibrillation. HR indicates hazard ratio; CI, confidence interval.

### **Figure 2.**

Kaplan-Meier curves for the incidences of stroke/systemic embolism (SE) (**A**), All-cause death (**B**), heart failure (HF) admission (**C**), and major bleeding (**D**) between asymptomatic and symptomatic patients with sustained atrial fibrillation. Abbreviations as in Figure 1.

**Tables****Table 1. Baseline clinical characteristics, co-morbidities, medical, and invasive treatment**

	PAF (1,837)			SAF (1,912)		
	Asymptomatic (689)	Symptomatic (1,148)	P value	Asymptomatic (1,282)	Symptomatic (630)	P value
<b>Baseline characteristics</b>						
Men	428 (62.1%)	638 (55.6%)	<0.01	813 (63.4%)	344 (54.6%)	<0.01
Age –yr, mean±SD	74.1±11.5	71.1±11.7	<0.01	75±10	74.7±10.1	0.497
BMI, mean±SD	22.9±4.1	22.9±3.7	0.692	23±3.8	23.4±4.5	0.099
Basic heart rate, bpm	77.7±15.9	75.3±15.9	<0.01	79.1±15.1	80.8±17.1	0.037
LVEF<40%	24/549 (4.4%)	35/919 (3.8%)	0.586	58/1026 (5.7%)	41/456 (9%)	0.024
LAD (mm), mean±SD	40.1±6.9	40.6±7.1	0.191	47±8.1	47.5±8	0.261
<b>Symptom type</b>						
palpitation	-	921 (80.2%)		-	303 (48.1%)	
orthopnea	-	204 (17.8%)		-	300 (47.6%)	
fatigue	-	129 (11.2%)		-	174 (27.6%)	
chest pain	-	75 (6.5%)		-	32 (5.1%)	
faintness	-	105 (9.1%)		-	65 (10.3%)	
<b>Co-morbidities</b>						
CHADS <sub>2</sub> , mean±SD	2.02±1.36	1.68±1.2	<0.01	2.22±1.38	2.25±1.33	0.72
CHA <sub>2</sub> DS <sub>2</sub> -VASC, mean±SD	3.37±1.73	2.99±1.63	<0.01	3.55±1.71	3.67±1.68	0.14
History of stroke/SE	158 (22.9%)	138 (12%)	<0.01	344 (26.8%)	129 (20.5%)	<0.01
Heart failure	133 (19.3%)	187 (16.3%)	0.112	387 (30.2%)	301 (47.8%)	<0.01
Hypertension	424 (61.5%)	729 (63.5%)	0.425	792 (61.8%)	384 (61%)	0.425
Diabetes mellitus	173 (25.1%)	243 (21.2%)	0.057	311 (24.3%)	138 (21.1%)	0.134
Coronary artery disease	119 (17.3%)	188 (16.4%)	0.651	136 (10.6%)	116 (18.4%)	<0.01
Chronic kidney disease	254 (36.9%)	341 (29.7%)	<0.01	492 (38.4%)	236 (37.5%)	0.726

	41 (6%)	25 (2.2%)	<0.01	64 (5%)	17 (2.7%)	0.021
History of major bleeding	41 (6%)	25 (2.2%)	<0.01	64 (5%)	17 (2.7%)	0.021
Peripheral artery disease	38 (5.5%)	41 (3.6%)	0.057	57 (4.4%)	17 (2.7%)	0.076
<b>Medical treatment</b>						
OAC at baseline	273 (40%)	472 (41.3%)	0.623	806 (63.2%)	447 (71.1%)	<0.01
Antiplatelet drugs	204 (29.9%)	321 (28.1%)	0.602	358 (28.1%)	173 (27.5%)	0.828
Class I AAD	145 (21.3%)	397 (34.7%)	<0.01	47 (3.7%)	92 (14.6%)	<0.01
Class III AAD	7 (1%)	8 (0.7%)	0.593	3 (0.2%)	3 (0.5%)	0.403
Bepridil	18 (2.6%)	38 (3.3%)	0.484	12 (0.9%)	8 (1.3%)	0.34
β-blockers	153 (22.4%)	334 (29.2%)	<0.01	340 (26.5%)	245 (38.9%)	<0.01
Calcium antagonists	221 (32.4%)	376 (32.9%)	0.837	380 (29.6%)	179 (28.4%)	0.426
Digitalis	37 (5.4%)	66 (5.8%)	0.834	251 (19.6%)	107 (17%)	0.202
Diuretics	156 (22.9%)	217 (19%)	0.048	416 (32.6%)	261 (41.5%)	<0.01
<b>Invasive treatment</b>						
Catheter ablation	28 (4.1%)	133 (11.6%)	<0.01	21 (1.6%)	50 (7.9%)	<0.01

Categorical data are presented as number (%). Continuous data are presented as mean ± standard deviation (SD). PAF: paroxysmal atrial fibrillation, SAF: sustained atrial fibrillation, BMI: body mass index, LVEF: left ventricular ejection fraction, LAD: left atrial diameter, SE: systemic embolism, OAC: oral anticoagulants, AAD: antiarrhythmic drug.

**Table 2. Indicators of the asymptomatic clinical status – Multivariable Analysis**

Variable	PAF			SAF		
	OR	95% CI	P value	OR	95% CI	P value
Heart failure	1.10	0.85-1.44	0.47	0.48	0.39-0.59	<0.01
Hypertension	0.87	0.71-1.07	0.18	1.03	0.84-1.26	0.81
Age ( $\geq 75$ years)	1.31	1.07-1.60	<0.01	1.04	0.85-1.28	0.70
Diabetes mellitus	1.18	0.94-1.50	0.16	1.22	0.96-1.55	0.11
History of stroke/SE	1.90	1.46-2.46	<0.01	1.35	1.06-1.72	0.016
History of major bleeding	2.09	1.24-3.54	<0.01	1.93	1.09-3.41	0.024
Male sex	1.36	1.11-1.66	<0.01	1.39	1.13-1.70	<0.01
Coronary artery disease	0.90	0.69-1.18	0.46	0.52	0.39-0.69	<0.01
Chronic kidney disease	1.26	1.02-1.57	0.035	1.35	1.09-1.68	<0.01

Data are presented as OR (odds ratio) and 95% CI (confidence interval).

PAF: paroxysmal atrial fibrillation, SAF: sustained atrial fibrillation, SE: systemic embolism.



**Table 3. Incidence of clinical events during follow-up (/100 person-years)**

Outcomes	PAF		SAF	
	Incidence rate	P value	Incidence rate	P value
<b>Stroke/SE</b>	1.79		2.59	
Asymptomatic	2.06	0.069	2.82	0.087
Symptomatic	1.63		2.13	
<b>All-cause death</b>	5.03		6.67	
Asymptomatic	7.25	<0.01	7.04	0.076
Symptomatic	3.70		5.92	
<b>HF admission</b>	2.33		4.35	
Asymptomatic	2.27	0.65	3.96	0.08
Symptomatic	2.37		5.15	
<b>Major bleeding</b>	1.66		1.87	
Asymptomatic	1.89	0.087	1.77	0.59
Symptomatic	1.53		2.07	

Data are presented as incidence rates (per 100 person-years). P value for comparison between asymptomatic versus symptomatic using a log-rank test.

PAF: paroxysmal atrial fibrillation, SAF: sustained atrial fibrillation, SE: systemic embolism, HF: heart failure.

**Table 4. Relative risk of asymptomatic status for major clinical events in the PAF patients  
- Multivariable Analysis**

	Entire Cohort			With OAC			Without OAC		
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Stroke/SE	1.28	0.82-2.01	0.28	1.05	0.52-2.11	0.90	1.46	0.79-2.71	0.23
All-cause death	1.71	1.31-2.29	<0.01	1.74	1.12-2.71	0.013	1.68	1.20-2.34	<0.01
HF admission	0.96	0.65-1.44	0.86	1.19	0.71-2.00	0.78	0.78	0.42-1.46	0.44
Major bleeding	1.18	0.74-1.90	0.48	1.57	0.77-3.20	0.21	0.93	0.48-1.79	0.83

Data are presented as HR (hazard ratio) and 95% CI (confidence interval).

HR was adjusted by age, body weight, history of stroke/SE, history of heart failure, hypertension, diabetes mellitus, coronary artery disease, peripheral artery disease, chronic kidney disease, and history of major bleeding.

PAF: paroxysmal atrial fibrillation, SE: systemic embolism, HF: heart failure, OAC: oral anticoagulants.

**Table 5. Risk factors of all-cause death in the PAF patients**  
**– Multivariable Analysis**

Variable	OR	95% CI	P value
Asymptomatic status	1.73	1.29-2.33	<0.01
Heart failure	2.77	1.99-3.86	<0.01
Hypertension	0.80	0.59-1.08	0.15
Age ( $\geq 75$ years)	2.56	1.86-3.53	<0.01
Diabetes mellitus	1.42	1.02-1.97	0.039
History of stroke/SE	1.95	1.36-2.80	<0.01
Male sex	1.24	0.92-1.68	0.16
Coronary artery disease	1.17	0.82-1.68	0.38
Chronic kidney disease	2.10	1.54-2.85	<0.01
History of major bleeding	2.09	1.15-3.81	0.015
OAC use	0.59	0.43-0.80	<0.01

Data are presented as OR (odds ratio) and 95% CI (confidence interval).


PAF: paroxysmal atrial fibrillation, SE: systemic embolism, OAC: oral anticoagulants.

# Figure 1

## PAF


**A**

### Stroke/SE




**B**

### All-cause death




**C**

### HF admission



**D**

### Major bleeding




# Figure 2

## SAF


**A**

### Stroke/SE




**B**

### All-cause death




**C**

### HF admission



**D**

### Major bleeding



**e-Appendix 1.****Working Group Members**

The following is a list of the institutions participating in the registry.

**Chief investigator:** Akao M (National Hospital Organization Kyoto Medical Center).

**Vice-chief investigator:** Chun YH (Ijinkai Takeda General Hospital).

**Steering Committee:** Esato M (Ijinkai Takeda General Hospital), Abe M (National Hospital Organization Kyoto Medical Center), Tsuji H (Tsuji Clinic), Furuke K (Furuke Clinic).

**Statistical Analysis:** Wada H (National Hospital Organization Kyoto Medical Center).

**Coordinator:** Ogawa T (Ogawa Medical Office), Tasato H (Tasato Clinic), Taniguchi Y (Taniguchi Clinic), Nishikawa M (Nishikawa Clinic), Furukawa K (Furukawa Medical Clinic), Kawai C, Hashimoto T, Kanda M (Ijinkai Takeda General Hospital), Tsukahara T, Fukuda S, Nakamura M, Ohtani R, Ito T, Hasegawa K (National Hospital Organization Kyoto Medical Center).

**Clinical Event Committee:** Kawabata Y, Yasuda K, Kameyama K (National Hospital Organization Kyoto Medical Center).

**Participating institutions:** Department of Cardiology, National Hospital Organization Kyoto Medical Center (Akao M, Abe M, Ogawa H, Masunaga N, Iguchi M, Ishii M, An Y, Unoki T, Niki S, Takabayashi K, Hamatani Y, Yamashita Y, Takagi D, Tezuka Y, Doi K, Aono Y, Ikeda S, Osakada G, Nakashima Y, Kanasaki M, Nakano T, Funatsu J, Nishio M, Takenaka Y); Department of Arrhythmia, Ijinkai Takeda General Hospital (Chun YH, Esato M, Kida Y, Nishina N); Koujinkai Oshima Hospital (Terada K); Division of Translational Research, National Hospital Organization Kyoto Medical Center (Hasegawa K, Wada H); Kanai Hospital (Nishio M, Kamiya Y, Abe M, Ishii M); Tsuji clinic (Tsuji H); Furukawa Medical Clinic (Furukawa K); Nishikawa Clinic (Nishikawa M); Taniguchi Clinic (Taniguchi Y); Gushiken Clinic (Gushiken T); Kyoto Rehabilitation Hospital (Hirata Y); Yoda Clinic (Yoda J); Tasato Clinic (Tasato H); Ogawa Medical Office (Ogawa T); Mukaijima Hospital (Wakatsuki Y, Yahata M, Higashitani N); Itoh Hemodialysis Clinic (Itoh H); Itoh Clinic (Itoh H, Ohmori Y); Ryokuhokai Tsuji Clinic (Tsuji K); Kitamura Clinic (Kitamura S); Izumikawa Clinic (Izumikawa F); Hirota Clinic (Hirota N); Kyomachi-Oota Clinic (Oota K); Kouseikai Rehabilitation Clinic (Kou K); Inariyama Takeda Hospital (Tanaka T, Iguchi M); Matsushita Clinic (Matsushita N); Kitani Clinic (Kitani K); Kimura Clinic (Kimura F); Hayashi Clinic (Hayashi S); Handa Clinic (Handa S); Soseikai General Hospital (Hasegawa S, Kono T, Otsuka K, Soyama A, Okamoto J, Nakai Y); Asamoto Clinic (Asamoto H); Sugano Clinic (Tanaka H, Murata T); Fushimi Momoyama General Hospital

(Kayawake S, Kinoshita Y); Furuke Clinic (Furuke K); Kanehisa Clinic (Asano N); Tahara Clinic (Tahara K); Matsumoto Medical Office (Matsumoto K); Kuroda Clinic (Kuroda O); Ochiai Clinic (Ochiai K, Ochiai J); Fujii Clinic (Fujii M); Kurihara Clinic (Kurihara M); Kuzuyama Clinic (Ito A); Kenkokai Fushimi Clinic (Totsuzaki S); Nakayama Orthopedic Clinic (Nakayama H); Department of Cardiovascular Medicine, Ijinkai Takeda General Hospital (Kawai C, Hashimoto T, Kakio T, Watanabe C, Takeda S, Sasaki Y, Shirasawa K, Beppu K, Inoue T, Shirasaka A, Doi T); Tatsumi Clinic (Ueda T); Oishi Clinic (Oishi M); Koizumi Clinic (Kasahara A); Kishida Clinic (Kishida Su, Kishida Sa); Shibata Clinic (Shibata M); Shimizu Clinic (Shimizu J); Shirasu Clinic (Shirasu M); Fujinokai Clinic (Tateishi S); Tsukuda Clinic (Tsukuda N); Shinseikai Tsuji Clinic (Tsuji K); Nishi Clinic (Nishi T); Nishimura Clinic (Nishimura S); Haba Clinic (Haba T); Higashimae Clinic (Higashimae R); Fujimori Clinic (Fujimori C); Hotta Clinic (Hotta T); Matsui Clinic (Matsui H, Matsui H); Shadan Matsumoto Clinic (Matsumoto H); Maruo Clinic (Maruo N); Misu Clinic (Mikami M); Mekata Clinic (Mekata H); Mori Pediatric Clinic (Mori H); Wakabayashi Clinic (Wakabayashi M); Nakatsugawa Clinic (Sasaki Z); Shiseikai Nishimura Clinic (Nishimura S); Yuge Eye Clinic (Yuge K); Gokita Hospital (Haruta M); Soseikai Clinic (Tsuda E); Toujinkai Hospital (Nishimura M); Kouno Clinic (Kouno T, Kouno Y); Matsumura Clinic (Matsumura S); Fujita Clinic (Fujita A); Takayasu Clinic (Takayasu F, Takayasu S), Yano Clinic (Yano Y), Niki Clinic (Niki S), Hasegawa Meiando Clinic (Hasegawa S), Watanabe Medical Clinic (Watanabe T).